On March 20, 2024, Steven Paul, M.D., a member of the Board of Directors of Sage Therapeutics, Inc. (the Company), notified the Board of his intention to retire from the Board when his current term ends at the company's 2024 annual meeting of stockholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.18 USD | +3.58% | +10.01% | -34.56% |
Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.56% | 824M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board